William Atkins
Wednesday, 07 January 2009 21:03
Science -
Biology
Page 2 of 3
Their paper entitled “
MTDH Activation by 8q22 Genomic Gain Promotes Chemoresistance and Metastasis of Poor-Prognosis Breast Cancer.”
Besides Drs. Chong, Kang, and Yang, the other researchers contributing to the study and paper are Michael Reiss, Guohong Hu, Yong Wei, Mario A. Blanco, Feng Li, Jessie L.-S. Au, and Bruce G. Haffty,
Dr. Yang is now with the Department of Breast Surgery, Qilu Hospital of Shandong University, Jinan, Shandong Province, China
They state in the abstract to their paper,
“Targeted therapy for metastatic diseases relies on the identification of functionally important metastasis genes from a large number of random genetic alterations.”
A computational algorithm (large database) was used to map alterations in recurrent genes that were thought to be related to the diagnosis of breast cancer and, in many cases, to a poor prognosis with the cancer.
From this analysis, 8q22 genomic gain was identified. It was found that 8q22 increases the chance of the metastasis of the gene metadherin (MTDH).
The 8q22 genomic gain was then validated with 250 samples of breast tumors as being present in over 40% of breast cancers and, when present, resulting in poor medical outcomes for the breast cancer patients.
Page three concludes.
